AHArgonde C. van Harten

Argonde C. van Harten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Argonde C. van Harten has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals

    by Calvin Trieu, Ellen Dicks, Diederick de Leeuw, Karlijn D.M. de Wit, Mardou S.S.A. Van Leeuwenstijn, Lisa-Marie Schlüter, Lynn Boonkamp, Frederik Barkhof, Mara Ten Kate, Elsmarieke van de Giessen, et al.

    Background and ObjectivesBlood-based biomarkers are reliable indicators of Alzheimer disease (AD)–related pathology in cognitively normal individuals. However, it remains unclear how changes in the...

  • Open Access

    SCD‐plus features and AD biomarkers in cognitively unimpaired samples: A meta‐analytic approach for nine cohort studies

    by Elizabeth Kuhn, Hannah M. Klinger, Rebecca E. Amariglio, Michael Wagner, Frank Jessen, Emrah Düzel, Michael T. Heneka, Gael Chételat, Dorene M. Rentz, Reisa A. Sperling, et al.

    INTRODUCTION: Specific features of subjective cognitive decline (SCD‐plus) have been proposed to indicate an increased risk of preclinical Alzheimer's disease (AD). However, few studies have examined how these features relate to AD biomarkers in cognitively unimpaired (CU) older adults.METHODS: Meta‐analyses were performed using cross‐sectional data from nine cohorts (n = 7219, mean age (SD): 71.17 (5.9), 56.5% female) to determine associations of SCD‐plus features with positron emission tomography (PET)– or cerebrospinal fluid (CSF)–derived amyloid beta (Aβ) and tau biomarkers.RESULTS: Participants with preclinical AD (community‐based only) were more likely to fulfill SCD‐plus features. The presence of self‐reported memory decline, associated concern/worry, and a higher number of fulfilled features were all associated with high Aβ levels. Only the latter was associated with abnormal tau.DISCUSSION: Simultaneous endorsement of multiple SCD‐plus features is a robust indicator of abnormal AD biomarkers in CU older adults, whereas isolated SCD features seem only sensitive to elevated Aβ, supporting their value as early behavioral markers of preclinical AD.Highlights: About two‐tenths of our sample had abnormal amyloid beta (Aβ) levels with evidence of subjective cognitive decline (SCD). Preclinical AD subsamples (community‐based) had a higher percentage of participants meeting SCD‐plus features. Self‐reported memory decline and concern/worry were the sole features associated with high Aβ, but not tau, burden. A higher number of fulfilled SCD‐plus features are linked to high Aβ and tau burden. Use of multiple SCD‐plus features may help identify early stages of biological AD.


  • Open Access

    Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia

    by Pieter J. van der Veere, Jeroen Hoogland, Leonie N.C. Visser, Argonde C. Van Harten, Hanneke F. Rhodius-Meester, Sietske A.M. Sikkes, Vikram Venkatraghavan, Frederik Barkhof, Charlotte E. Teunissen, Elsmarieke van de Giessen, et al.

    Cognitive decline rates in Alzheimer disease (AD) vary greatly. Disease-modifying treatments may alter cognitive decline trajectories, rendering their prediction increasingly relevant. We aimed to construct clinically applicable prediction models of cognitive decline in amyloid-positive patients with mild cognitive impairment (MCI) or mild dementia. From the Amsterdam Dementia Cohort, we selected amyloid-positive participants with MCI or mild dementia and at least 2 longitudinal Mini-Mental State Examination (MMSE) measurements. Amyloid positivity was based on CSF AD biomarker concentrations or amyloid PET. We used linear mixed modeling to predict MMSE over time, describing trajectories using a cubic time curve and interactions between linear time and the baseline predictors age, sex, baseline MMSE, APOE ε4 dose, CSF β-amyloid (Aβ) 1-42 and pTau, and MRI total brain and hippocampal volume. Backward selection was used to reduce model complexity. These models can predict MMSE over follow-up or the time to an MMSE value. MCI and mild dementia were modeled separately. Internal 5-fold cross-validation was performed to calculate the explained variance (R2). In total, 961 participants were included (age 65 ± 7 years, 49% female), 310 had MCI (MMSE 26 ± 2) and 651 had mild dementia (MMSE 22 ± 4), with 4 ± 2 measurements over 2 (interquartile range 1-4) years. Cognitive decline rates increased over time for both MCI and mild dementia (model comparisons linear vs squared vs cubic time fit; p < 0.05 favoring a cubic fit). For MCI, backward selection retained age, sex, and CSF Aβ1-42 and pTau concentrations as time-varying effects altering the MMSE trajectory. For mild dementia, retained time-varying effects were Aβ1-42, age, APOE ε4, and baseline MMSE. R2 was 0.15 for the MCI model and 0.26 for mild dementia in internal cross-validation. A hypothetical patient with MCI, baseline MMSE 28, and CSF Aβ1-42 of 925 pg/mL was predicted to reach an MMSE of 20 after 6.0 years (95% CI 5.4-6.7) and after 8.6 years with a hypothetical treatment reducing decline by 30%. We constructed models for MCI and mild dementia that predict MMSE over time. These models could inform patients about their potential cognitive trajectory and the remaining uncertainty and aid in conversations about individualized potential treatment effects.


  • Open Access

    Mastermind of the Alzheimer’s blood‐based biomarkers: development of cutoffs and a visualization tool for use in clinical practice

    by Inge M.W. Verberk, Maurice Y. Kingma, Argonde C. van Harten, Anouk Den Braber, Sinthujah Vigneswaran, Mariam Gouda, Marie‐Paule E. van Engelen, Afina W. Lemstra, Yolande A.L. Pijnenburg, Wiesje M. van der Flier, et al.

    Background: Phosphorylated (P‐)tau, amyloid‐beta (Abeta)1‐42/1‐40, glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) are the current key Alzheimer’s disease (AD) blood‐based biomarkers. Interpreting results of the four biomarkers simultaneously in a clinical context is challenging. A decision algorithm could aid in the interpretation, tailored to clinically relevant questions: 1) identify positive amyloid status among preclinical and prodromal AD stages, 2) discriminate AD‐dementia from frontotemporal dementia (FTD), 3) discriminate AD‐dementia from dementia with Lewy bodies (DLB). We aimed to develop such an interpretation tool.Method: We included 1199 participants from the Amsterdam Dementia Cohort (table 1) with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD‐dementia, FTD (mixed pathologies) or DLB. Plasma P‐tau181, Abeta1‐42/1‐40, GFAP and NfL were measured with Simoa. NfL levels were adjusted for age (method: https://doi.org/10.1002/acn3.51676). We used LASSO regression with bootstrap (1000 iterations) to identify which plasma markers robustly contribute to the prediction of the outcomes of our clinically relevant questions. When a marker was selected in >95% of the iterations in at least one of the clinical scenarios, we qualified it as a contributing marker. Subsequently, we constructed UpSet plots applying Youden’s cutoffs as interpretation tool for the plasma results.Result: P‐tau181, GFAP and NfL were selected as contributing biomarkers. Abeta1‐42/1‐40 was not selected. The panel of P‐tau181, GFAP and NfL had an AUC = 83% (95%CI: 76‐90%) to identify amyloid positivity in SCD+MCI, AUC = 87% (95%CI: 79‐94%) to differentiate AD‐dementia from FTD, and AUC = 73% (95%CI: 62‐84%) to differentiate AD‐dementia from DLB. The UpSet plots show the simultaneous interpretation of P‐tau181, GFAP and NfL results for each clinically relevant question (figure 1): e.g., when all three biomarkers are abnormal in participants with SCD+MCI, there is 83% agreement with an abnormal PET or CSF amyloid status, and when all three plasma markers are normal, there is 88% agreement with a normal amyloid status.Conclusion: The combination of P‐tau181, GFAP and NfL in plasma could support decision making in different clinical contexts. UpSet plots enable easy interpretation of a combination of the markers, and could serve as a tool to support both detection and differential diagnosis of Alzheimer’s disease.


  • Open Access

    CSF Proteomic Signatures are Associated With Cognitive Decline in the Alzheimer’s Disease Continuum

    by Ellen M. Vromen, Argonde C. van Harten, Frode Berven, Charlotte E. Teunissen, Wiesje M. van der Flier, Yolande A.L. Pijnenburg, Pieter Jelle Visser, Betty M. Tijms

    Background: Individuals with Alzheimer’s disease (AD) show variability in cognitive decline. Little is known about the underlying biological processes. Using an untargeted CSF proteomics approach, we explored the biological processes associated with cognitive decline throughout the AD continuum.Method: We included 280 AD individuals from the Amsterdam Dementia Cohort (median age 66 (IQR:60‐70) years, 124 (44%) female, n = 34 preclinical AD, n = 77 MCI due to AD, n = 169 AD‐dementia, all abnormal CSF amyloid, Table 1). The CSF proteome was quantified at baseline using LC‐MS/MS in an untargeted manner based on TMT labelingWe included n = 2318 proteins measured in ≥50% individuals. We used the MMSE score as a proxy for global cognition, and created summary scores for cognitive domains (i.e., episodic memory, executive functioning, attention and language) using neuropsychological test scores. We applied linear mixed models to test the association between each protein and cognitive decline over time, with age, sex and education as covariates, a random intercept for patient ID, and a random slope for time; stratified for syndrome diagnosis. We performed pathway enrichment analysis on proteins associated with cognitive decline.Result: Individuals with preclinical AD showed most decline on episodic memory compared to other domains. In preclinical AD, 150 proteins, enriched for cell death and cell adhesion, were associated with memory decline. Individuals with MCI showed most decline on episodic memory and executive functioning. Proteins associated with decline on memory (n = 188, Figure 1) and executive functioning (n = 213) were enriched for complement and coagulation cascade and innate immune processes. Proteins associated with memory decline were also enriched for synaptic plasticity. Individuals with AD‐dementia showed more decline on attention and language compared to other AD‐stages. In AD‐dementia, 69 proteins, enriched for innate immune processes, were associated with decline on the MMSE and 127 proteins, enriched for synaptic plasticity, were associated with decline on language.Conclusion: Proteins involved in innate immune processes, synaptic plasticity and cell death were associated with cognitive decline in AD, with different processes involved in different stages. These results provide insight into the pathophysiology of cognitive decline and hint towards potential therapeutic targets for prevention of cognitive decline in AD.

  • Open Access

    The association between AD biomarkers and neuropsychiatric symptoms in subjective cognitive decline; the SCIENCe project

    by Calvin Trieu, Argonde C. van Harten, Mardou S. S. A. van Leeuwenstijn, Lior A. Kroeze, Jarith L. Ebenau, Inge M.W. Verberk, Sietske A.M. Sikkes, Sander C.J. Verfaillie, Elsmarieke Giessen, Charlotte E. Teunissen, et al.

    Background: Neuropsychiatric symptoms (NPS) are increasingly recognized as non‐cognitive manifestation of Alzheimer’s disease (AD). However, the relationship between AD‐related pathology and NPS remains unclear. We aimed to investigate the cross‐sectional association between Alzheimer biomarkers and neuropsychiatric symptoms (NPS) in individuals with subjective cognitive decline (SCD) presenting at a memory clinic. In addition, we evaluated personality traits and education as potentially modifying factors of this association.Method: We included 346 individuals with SCD (age: 62.9±7.8) from the SCIENCe cohort, including 92 amyloid positive participants (age: 66.4±7.0, Female: 44.6%, MMSE: 28.5±1.3) and 254 amyloid negative participants (age: 61.6±7.7, Female: 40.6%, MMSE: 28.6±1.3). Amyloid status was determined by amyloid PET or CSF biomarkers according to visual read or established cut points. Neuropsychiatric symptoms were assessed using the Geriatric Depression Scale (GDS; n = 282), the Center for Epidemiological Studies‐Depression (CES‐D; n = 225), the Hospital Anxiety and Depression Scale – anxiety subscale (HADS‐A; n = 225) and the Neuropsychiatric Inventory Questionnaire (NPI‐Q; n = 198). We used linear regression analyses, adjusted for age and sex, to assess the association between amyloid status and NPS. In secondary analyses, we tested for interactions between amyloid status and (1) neuroticism (Dutch Personality Questionnaire), (2) somatization, (Four‐Dimensional Symptom Questionnaire), and (3) educational level (Dutch Verhage scale).Result: Amyloid status was not associated with GDS, CES‐D, HADS‐A and NPI‐Q scores in univariable analyses. When we evaluated effect modification, we found an interaction between amyloid status and neuroticism in the association with NPI‐Q (p<0.05), indicating a positive association between amyloid status and NPS in participants with a low level of neuroticism (β: 2.56±2.24), and a negative association in participants with a high level of neuroticism (β: ‐4.09±3.23).Conclusion: In this cross‐sectional analysis in individuals with SCD, amyloid status was hardly associated with neuropsychiatric symptoms. In future studies, we focus on amyloid status as determinant of change in NPS over time.

  • Open Access

    Plasma pTau‐217 and NfL concentrations across diagnoses in an unselected memory clinic cohort

    by Rebecca Z. Rousset, Inge M.W. Verberk, Afina W. Lemstra, Yolande A.L. Pijnenburg, Wiesje M. van der Flier, Andreas Jeromin, Anouk Den Braber, Argonde C. van Harten, Charlotte E. Teunissen

    Background: Alzheimer’s Disease (AD) plasma biomarkers have been proposed for amyloid positivity identification and for differentiating between diagnoses. Phosphorylated Tau‐217 (pTau‐217) has demonstrated good predictive ability for AD vs healthy controls. Neurofilament Light chain (NfL) differentiates between Frontotemporal Dementia (FTD) and other dementia. These factors have not be extensively tested in real‐world cohorts. The aim of this study was to investigate how pTau‐217 and NfL concentrations differ across clinical diagnoses in an unselected, real‐world memory clinic cohort.Method: We included 418 consecutive patients from the Amsterdam Dementia Cohort. Patients were split among 12 diagnoses, including SCD, Mild Cognitive Impairment (MCI), probable AD, Dementia with Lewy Bodies (DLB) and FTD (Table 1). pTau‐217 was measured using the novel AlzPath assay, while NfL was measured using the Quanterix Simoa assay. were used to classify patients as high or low for pTau‐217 and NfL levels. The pTau‐217 cutoff (0.58 pg/mL) was the Youden index cutoff derived from the present data, based on amyloid‐positive AD vs amyloid‐negative SCD diagnosis (n = 57), using amyloid status derived from cerebrospinal fluid or Amyloid positron emission tomography for classification. (18.2 pg/mL) was chosen based on the sample’s median age (64 years) and taking the value associated with the 90th percentile of normal NfL levels (NfL interface for physicians (shinyapps.io)).Result: pTau‐217 levels were highest in patients with AD and Primary Progressive Aphasia (PPA), and lowest in those with Vascular Dementia (VaD) and other neurological diagnosis (Figure 1). NfL levels were highest in patients with VaD and FTD, and lowest in SCD and psychiatric diagnoses. The cutoffs highlighted similar trends, with higher proportions patients with elevated pTau‐217 levels observed in possible and probable AD, MCI, and DLB. Higher proportions of patients with high NfL levels were observed in FTD, PPA, VaD, and possible AD (Figure 2).Conclusion: pTau‐217 concentrations vary as expected across the different diagnoses, with highest concentrations in AD pathology diagnostic groups. The elevated levels observed in DLB and PPA could be due to underlying AD co‐pathology. Following previous results, NfL concentrations were highest in FTD and lowest in psychiatry and SCD.

  • Open Access

    Plasma biomarkers as a diagnostic tool for amyloid status: factors affecting the frequency of false positive and false negative results

    by Rebecca Z. Rousset, Inge M.W. Verberk, Argonde C. van Harten, Wiesje M. van der Flier, Afina W. Lemstra, Yolande A.L. Pijnenburg, David Wilson, Anouk Den Braber, Charlotte E. Teunissen

    Background: Amyloid Positron Emission Tomography (PET) and Cerebrospinal fluid (CSF) analysis are used to diagnose Alzheimer’s Disease (AD). Plasma biomarkers have been proposed as a cost‐effective and less invasive AD diagnostic tool. The main diagnostic markers of interest are Amyloid‐beta1‐42/1‐40 (Abeta1‐42/1‐40), phosphorylated Tau‐181 (pTau181), Glial Fibrillary Acidic Protein (GFAP), and Neurofilament Light chain (NfL). These markers have good predictive potential for AD diagnosis, but there is also disagreements between plasma analysis and amyloid status through PET/CSF analysis for a significant number of patients. We aim to identify factors that could account for discordancy of plasma and PET/CSF results.Method: 1183 participants were included from the Amsterdam Dementia Cohort (Table 1). Amyloid status was determined by Amyloid PET or CSF. Plasma Abeta1‐42/1‐40, pTau181, NfL and GFAP were measured and included of amyloid status in a multivariate logistic regression model. This logistic model was applied back in the cohort, returning a probability of amyloid positivity for each patient based on their plasma biomarkers concentrations. These probabilities were used to classify patients as plasma positive (≥ 0.5) or plasma negative (< 0.5). Analysis was carried out in 2 groups: patients with positive CSF/PET amyloid status and patients with negative CSF/PET amyloid status. Univariate logistic regression models were applied to identify demographic factors, comorbidities or medications associated with false negative (negative plasma status, positive CSF/PET amyloid status) and false positive (positive plasma status, negative CSF/PET amyloid status) cases.Result: 1183 patients had an amyloid status based on CSF or PET, of which 130 had false negative (10.99%), 106 had false positive (8.96%), 451 (38.12%) had true negative and 496 (41.93%) had true positive plasma results. Higher MMSE scores were associated with higher odds of having a false negative plasma status. Older age, having suffered a stroke, and impaired kidney function were associated with higher odds of false positive plasma results (Table 2).Conclusion: We identified MMSE score to be associated with false negative plasma results, and age, stroke, and kidney function to be associated with false positive plasma results. Adjusting for these factors may improve predictive ability of plasma biomarkers and AD diagnostic accuracy.

  • Open Access

    Innovative recruitment strategies for a multi‐domain lifestyle intervention trial (FINGER‐NL) via the Dutch Brain Research Registry

    by Lisa Waterink, Lion M. Soons, Jikke T. Boelens Keun, Argonde C. van Harten, Sietske A.M. Sikkes, Erik J.A. Scherder, Kay Deckers, Sebastian Köhler, Wiesje M. Flier, Marissa D. Zwan

    Background: Finding eligible participants for dementia prevention trials is challenging, resulting in prolonged recruitment periods, underpowered studies, and excessive costs. The Dutch Brain Research Registry (DBRR) is an online platform to facilitate recruitment of research participants. We evaluated different recruitment strategies with the ambition to optimize recruitment for the multi‐domain lifestyle intervention trial FINGER‐NL.Method: DBRR registrants were prescreened for FINGER‐NL based on available profile information. Potentially eligible registrants received an automatic study invitation. Those interested were contacted for additional telephonic screening and, if eligible, included in the trial. Five recruitment strategies within 2022 were executed with the goal to increase the number of DBRR registrants: 1) a paid Facebook‐campaign, 2) referral via (patient)‐organizations, 3) newspaper articles, 4) live‐events, and 5) national television appearance (W.F&E.S.). Recruitment source was traced (online; UTM tags) and/or reported by the participant. For most recruitment strategies, we involved a nationally well‐known ambassador (E.S.) who advocates a healthy lifestyle to improve brain‐health (Figure 1). For each strategy, we described the number of individuals registered, eligible and included in FINGER‐NL. We calculated efficiency (%eligible/prescreened) as a reflection of the proportion of eligible participants reached, and effectiveness (%included/registered) as a reflection of the proportion of participants included in FINGER‐NLResult: In 2022, the DBRR recruited 11234 new registrants. The highest numbers of registrants and highest number of inclusions were reached with national television appearance and the Facebook‐campaign (Table 1). In particular, the Facebook advertisement with a lifestyle theme and well‐known ambassador outperformed all other advertisements in number of registrations (Figure 1). After initial prescreening, between 18‐35% of registrants were eligible. Most efficient were national television and the Facebook‐campaign. Between 4‐12% of new registrants were included in the trial. Most effective strategies were national television appearance and referrals via patient‐organizationsConclusion: Our results show that mass‐media, i.e. tailor‐made Facebook‐campaigns, national television appearance and events, are efficient ways to reach large numbers of eligible participants, especially when well‐known ambassador(s) were included. Recruitment strategies with detailed information about in‐ and exclusion of the trial are most effective. The DBRR provides an efficient and effective recruitment and prescreening process for the FINGER‐NL trial.

  • Open Access

    Predicting cognitive decline in amyloid‐positive patients with mild cognitive impairment or mild dementia

    by Pieter J. van der Veere, Jeroen Hoogland, Leonie N.C. Visser, Argonde C. van Harten, Hanneke F.M. Rhodius‐ Meester, Frederik Barkhof, Charlotte E. Teunissen, Elsmarieke van de Giessen, Johannes Berkhof, Wiesje M. van der Flier

    Background: Cognitive decline rates in Alzheimer’s disease (AD) vary greatly. Disease‐modifying treatments (DMT) may alter cognitive decline trajectories, rendering their prediction increasingly relevant. We aimed to construct clinically applicable prediction models of cognitive decline in amyloid‐positive patients with mild cognitive impairment (MCI) or mild dementia.Methods: From the Amsterdam Dementia Cohort, we selected amyloid‐positive participants with MCI (n = 317, 66±7yrs, 45%Female, baseline MMSE 26±2) or mild dementia (n = 666, 65±7yrs, 49%Female, MMSE 22±4) and ≥2 annual MMSEs. Follow‐up was 3±2yrs with 4±2 MMSEs. Amyloid positivity was based on cerebrospinal fluid (CSF) AD biomarker concentrations or amyloid PET. We used linear mixed modelling to predict MMSE over time. First, decline trajectories were described with cubic time curves (S‐shaped). Then, we backwards selected predictors from baseline MMSE, age, sex, APOE ε4 dose, magnetic resonance imaging (MRI; visual scores: medial temporal lobe [MTA], global atrophy), CSF concentrations (phosphorylated tau [pTau], Aβ1‐42), and their interactions with linear time. MCI and mild dementia were modelled separately as stratification increased log‐likelihood.Results: For MCI and mild dementia, rates of cognitive decline increased over time. In MCI, average MMSE declined from 26.4(95%CI:26.2‐26.7) to 25.8(25.5‐26.1) after 18 months, to 24.2(23.7‐24.6) after three years, and to 21.0(20.1‐21.7) after five years. In mild dementia, MMSE declined from 22.4(95%CI:22.0‐22.6) to 19.8(19.4‐20.2), 15.3(14.6‐15.9), and 7.8(6.7‐8.9). For MCI, selected predictors of future MMSE were baseline MMSE, and interactions of time with age, MTA and pTau (table 1). For mild dementia, additional selected interactions with time were baseline MMSE, Aβ1‐42, and APOE ε4. Figure 1 shows the predicted decline distribution. As an example; predicted MMSE after three years for a 65yrs female MCI patient with baseline MMSE 27, would be 26.3 with MTA 0 and pTau 20pg/ml, compared to 23.8 with MTA 1 and pTau 40pg/ml (figure 2a;2b). In the latter case, 27% slower decline would lengthen follow‐up to a predicted MMSE of twenty by fourteen months.Conclusion: We constructed models for MCI and mild dementia that predict MMSE over time. These models could inform patients about their potential cognitive trajectory and aid in conversations about DMT initiation and the evaluation of their potential effect.